BR0307627A - Métodos e composições para o tratamento de doenças do olho - Google Patents

Métodos e composições para o tratamento de doenças do olho

Info

Publication number
BR0307627A
BR0307627A BR0307627-0A BR0307627A BR0307627A BR 0307627 A BR0307627 A BR 0307627A BR 0307627 A BR0307627 A BR 0307627A BR 0307627 A BR0307627 A BR 0307627A
Authority
BR
Brazil
Prior art keywords
compositions
methods
eye diseases
treating eye
eye
Prior art date
Application number
BR0307627-0A
Other languages
English (en)
Inventor
Hans-Markus Bender
Ulrich Lang
Mathias Wiesner
Martin Frieldlander
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0307627A publication Critical patent/BR0307627A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODOS E COMPOSIçõES PARA O TRATAMENTO DE DOENçAS DO OLHO". A presente invenção refere-se a métodos e composições destinados à profilaxia e/ou tratamento de doenças do olho, usando antagonistas de receptores de integrina <244>~ v~<225>~ 3~ e/ou <244>~ v~<225>~ 5~. As composições podem ser nanopartículas e são administradas ao olho mediante injeção dentro do subespaço de Tenon do olho.
BR0307627-0A 2002-02-14 2003-02-12 Métodos e composições para o tratamento de doenças do olho BR0307627A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02003432 2002-02-14
PCT/EP2003/001369 WO2003068253A1 (en) 2002-02-14 2003-02-12 Methods and compositions for the treatment of eye diseases

Publications (1)

Publication Number Publication Date
BR0307627A true BR0307627A (pt) 2005-01-11

Family

ID=27675621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307627-0A BR0307627A (pt) 2002-02-14 2003-02-12 Métodos e composições para o tratamento de doenças do olho

Country Status (13)

Country Link
US (1) US20050085415A1 (pt)
EP (1) EP1474162A1 (pt)
JP (1) JP2005517038A (pt)
KR (1) KR20040091002A (pt)
CN (1) CN1658894A (pt)
AU (1) AU2003208833A1 (pt)
BR (1) BR0307627A (pt)
CA (1) CA2476120A1 (pt)
MX (1) MXPA04007770A (pt)
PL (1) PL371281A1 (pt)
RU (1) RU2004127577A (pt)
WO (1) WO2003068253A1 (pt)
ZA (1) ZA200407335B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1835735B (zh) * 2003-08-20 2010-05-12 参天制药株式会社 微粒眼球筋膜下给药的药物释放系统
WO2006003519A2 (en) * 2004-07-02 2006-01-12 Novagali Pharma Sa Use of emulsions for intra: and periocular injection
JP2006257080A (ja) * 2005-02-18 2006-09-28 Santen Pharmaceut Co Ltd ステロイド化合物の副作用軽減または回避方法
WO2008054341A2 (en) * 2005-06-20 2008-05-08 The Research Foundation Of State University Of New York Method of bioimaging using nanocrystals of fluorescent dyes
EP3108933B1 (en) * 2008-01-07 2019-09-18 Salutaris Medical Devices, Inc. Devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye
US8608632B1 (en) * 2009-07-03 2013-12-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye
US9873001B2 (en) 2008-01-07 2018-01-23 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US9056201B1 (en) * 2008-01-07 2015-06-16 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US10022558B1 (en) 2008-01-07 2018-07-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
CN102149728B (zh) * 2008-09-10 2014-10-15 霍夫曼-拉罗奇有限公司 抑制眼部血管生成的方法
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
USD815285S1 (en) 2016-05-11 2018-04-10 Salutaris Medical Devices, Inc. Brachytherapy device
USD814638S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD814637S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD808529S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device
USD808528S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904649A (en) * 1986-05-23 1990-02-27 New England Medical Center Hospitals, Inc. Method and solution for treating glaucoma
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
FR2678168B1 (fr) * 1991-06-28 1993-09-03 Rhone Poulenc Rorer Sa Nanoparticules ayant un temps de capture par le dysteme reticulo endothelial allonge.
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0754046A1 (en) * 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
US5980929A (en) * 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE60018777T2 (de) * 1999-10-21 2006-02-02 Alcon Inc. Medikamentenversorgung der sub-tenon
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
MXPA03003741A (es) * 2000-11-01 2003-07-28 Merck Patent Gmbh Metodos y composiciones para el tratamiento de enfermedades oftalmicas.

Also Published As

Publication number Publication date
AU2003208833A1 (en) 2003-09-04
RU2004127577A (ru) 2005-05-27
WO2003068253A1 (en) 2003-08-21
CA2476120A1 (en) 2003-08-21
CN1658894A (zh) 2005-08-24
US20050085415A1 (en) 2005-04-21
MXPA04007770A (es) 2004-10-15
KR20040091002A (ko) 2004-10-27
JP2005517038A (ja) 2005-06-09
ZA200407335B (en) 2005-09-28
PL371281A1 (en) 2005-06-13
EP1474162A1 (en) 2004-11-10

Similar Documents

Publication Publication Date Title
BR0307627A (pt) Métodos e composições para o tratamento de doenças do olho
BR0211604A (pt) Inibidores de integrina para o tratamento de doenças do olho
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2005072308A3 (en) Cgrp receptor antagonists
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
GB0223038D0 (en) Therapeutic compounds
TW200505903A (en) CGRP receptor antagonists
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
GB0225474D0 (en) Therapeutic agents
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
RS20050199A (en) Imidazolopyridines and methods of making and using the same
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.